NASDAQHealth CareDiagnostics & ResearchSnapshot 2026-07-23
Reading BDSX? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
BDSX is positioned as a growth-oriented investment with a focus on increasing revenue and achieving adjusted EBITDA positivity. The current thesis is stable, supported by recent earnings beats and management's commitment to growth.
The market appears to price in a low level of fragility, indicating that expectations for BDSX are somewhat justified compared to peers. However, there is a notable expectations gap, suggesting that while the stock may be seen as cheap, there is uncertainty about future performance.
Management has successfully increased revenue guidance and demonstrated consistent revenue growth, indicating a positive trajectory. However, the company remains loss-making, and achieving adjusted EBITDA positivity is mixed, which adds some risk.
The long-term thesis hinges on the performance of sector bellwethers like TMO, DHR, and IDXX. If these companies continue to perform well, it could provide a favorable environment for BDSX. Conversely, any negative guidance from these peers could pose risks to BDSX's growth outlook.
Overall, BDSX's growth strategy is intact, but it faces risks from broader market conditions. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: An increase in revenue guidance shows strong growth momentum. It confirms management's commitment to growth.
Confirms:Management raises FY 2026 revenue guidance to more than $114 million.
Disproves:Management keeps FY 2026 revenue guidance at or below $108 million.
Why it matters: Exceeding this growth rate would confirm strong demand and operational efficiency. It would also support the raised full-year guidance.
Confirms:Q2 2026 revenue growth exceeds 25% year-over-year.
Disproves:Q2 2026 revenue growth is 25% or lower year-over-year.
Why it matters: Positive adjusted EBITDA shows better financial health. It means the company is managing costs well.
Confirms:Adjusted EBITDA turns positive for the next quarter.
Disproves:Adjusted EBITDA stays negative for the next quarter.
Why it matters: The earnings report will show if Biodesix can improve its financial performance. Investors will look for signs of recovery.
Confirms one read:Earnings show a smaller loss than last quarter. This means better performance.
Confirms the other:Earnings report shows a larger loss than the previous quarter, signaling ongoing struggles.
Why it matters: If health care revenue growth speeds up, it could help Biodesix's outlook. A strong sector can lift individual companies.
Confirms:Health care revenue growth rises back toward 10% year over year.
Disproves:Health care revenue growth continues to slow below 10% year over year.
Why it matters: If test volumes rise above this level, it shows strong market demand and good sales.
Confirms:Test volumes grow more than 25% year-over-year in Q2 2026.
Disproves:Test volumes grow 25% or lower year-over-year in Q2 2026.
